loading
Kazia Therapeutics Limited Adr stock is traded at $8.12, with a volume of 9,904. It is down -1.46% in the last 24 hours and up +18.97% over the past month. Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
See More
Previous Close:
$8.24
Open:
$8.17
24h Volume:
9,904
Relative Volume:
0.01
Market Cap:
$9.08M
Revenue:
-
Net Income/Loss:
$-13.52M
P/E Ratio:
-10.97
EPS:
-0.74
Net Cash Flow:
$-10.03M
1W Performance:
-0.73%
1M Performance:
+18.97%
6M Performance:
+28.88%
1Y Performance:
-58.57%
1-Day Range:
Value
$7.86
$8.46
1-Week Range:
Value
$7.8527
$8.99
52-Week Range:
Value
$2.86
$39.05

Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile

Name
Name
Kazia Therapeutics Limited Adr
Name
Phone
01161298780088
Name
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Name
Employee
7
Name
Twitter
@KaziaTx
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
KZIA's Discussions on Twitter

Compare KZIA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KZIA
Kazia Therapeutics Limited Adr
8.12 9.69M 0 -13.52M -10.03M -0.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-06-25 Initiated Maxim Group Buy
Oct-14-21 Initiated Maxim Group Buy
Jan-05-21 Initiated H.C. Wainwright Buy

Kazia Therapeutics Limited Adr Stock (KZIA) Latest News

pulisher
Aug 04, 2025

Novogen Limited (NASDAQ:KZIA) Sees Large Growth in Short Interest - Defense World

Aug 04, 2025
pulisher
Aug 01, 2025

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - The Manila Times

Aug 01, 2025
pulisher
Aug 01, 2025

Kazia Therapeutics raises US$2m via discounted private placement to fund trials | KZIA SEC FilingForm 6-K - Stock Titan

Aug 01, 2025
pulisher
Jul 26, 2025

Kazia Therapeutics Announces At the Market Offering Agreement - The Globe and Mail

Jul 26, 2025
pulisher
Jul 25, 2025

Kazia Therapeutics starts US$1.9M ATM ADS program; CEO exits board | KZIA SEC FilingForm 6-K - Stock Titan

Jul 25, 2025
pulisher
Jul 15, 2025

Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - Barchart.com

Jul 15, 2025
pulisher
Jul 14, 2025

Novogen (NASDAQ:KZIA) Raised to “Sell” at Wall Street Zen - ETF Daily News

Jul 14, 2025
pulisher
Jul 14, 2025

Analysts Issue Forecasts for Novogen FY2025 Earnings - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

Novogen (NASDAQ:KZIA) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Novogen (NASDAQ:KZIA) Rating Increased to Strong-Buy at HC Wainwright - Defense World

Jul 12, 2025
pulisher
Jul 10, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Novogen (NASDAQ:KZIA) Shares Up 39.7% – Should You Buy? - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

Ryde Group files US$100 M shelf; micro-cap float limits near-term raise | KZIA SEC FilingForm 424B3 - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Cancer Innovation Accelerates As Funding Cuts Loom And Biotechs Step Up - Barchart.com

Jul 09, 2025
pulisher
Jul 09, 2025

Kazia Therapeutics stock soars after positive early cancer treatment data By Investing.com - Investing.com Nigeria

Jul 09, 2025
pulisher
Jul 09, 2025

Kazia Therapeutics stock soars after positive early cancer treatment data - Investing.com Australia

Jul 09, 2025
pulisher
Jul 09, 2025

Early Clinical Trial: New Drug Combo Slashes Breast Cancer Cells by 50% in Just 21 Days - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - Ariva

Jul 09, 2025
pulisher
Jun 20, 2025

Short Interest in Novogen Limited (NASDAQ:KZIA) Declines By 28.0% - Defense World

Jun 20, 2025
pulisher
Jun 13, 2025

Biotech Stocks To Add to Your Watchlist – June 11th - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Kazia Therapeutics (NASDAQ:KZIA) Receives Buy Rating from Maxim Group - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

United States shares lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com India

Jun 12, 2025
pulisher
Jun 11, 2025

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com UK

Jun 11, 2025
pulisher
Jun 11, 2025

Kazia’s paxalisib shows promise in breast cancer preclinical study - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Kazia’s paxalisib shows promise in breast cancer preclinical study By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough: New Drug Paxalisib Successfully Combats Triple-Negative Breast Cancer Resistance in Preclinical Study - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development - TipRanks

Jun 10, 2025
pulisher
Jun 05, 2025

Kazia's Brain Cancer Drug Now Targets Breast Cancer: First Patient Starts Groundbreaking Combination Trial - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Kazia Therapeutics (NASDAQ:KZIA) Stock Price Up 26.7% – What’s Next? - Defense World

Jun 04, 2025
pulisher
May 29, 2025

KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY - Barchart.com

May 29, 2025
pulisher
May 26, 2025

Breast Cancer Treatment Market to reach $72B by 2033 with 9.4% CAGR growth | DataM IntelligenceNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA

May 26, 2025
pulisher
May 24, 2025

Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail

May 24, 2025
pulisher
May 21, 2025

Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight - The Globe and Mail

May 21, 2025
pulisher
May 15, 2025

Kazia Therapeutics Highlights Recent Progress and Provides Business Update – Company Announcement - Financial Times

May 15, 2025
pulisher
May 15, 2025

Kazia's Breakthrough: FDA Green Light for Glioblastoma Trial Plus Major Pipeline Expansion in Breast Cancer - Stock Titan

May 15, 2025
pulisher
May 13, 2025

KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Barclays PLC Invests $212,000 in Kazia Therapeutics Limited (NASDAQ:KZIA) - Defense World

May 13, 2025
pulisher
May 10, 2025

Kazia Therapeutics (NASDAQ:KZIA) Shares Up 14.1% – Should You Buy? - Defense World

May 10, 2025
pulisher
May 08, 2025

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE - marketscreener.com

May 08, 2025
pulisher
May 03, 2025

KZIAKazia Therapeuti Latest Stock News & Market Updates - Stock Titan

May 03, 2025
pulisher
Apr 18, 2025

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS - marketscreener.com

Apr 18, 2025
pulisher
Apr 18, 2025

United States shares mixed at close of trade; Dow Jones Industrial Average down 1.33% - Investing.com India

Apr 18, 2025
pulisher
Apr 18, 2025

Kazia announces voluntary delisting from ASX - marketscreener.com

Apr 18, 2025
pulisher
Apr 18, 2025

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA - marketscreener.com

Apr 18, 2025
pulisher
Apr 17, 2025

GBM AGILE OPENS TO PAXALISIB IN EUROPE - MarketScreener

Apr 17, 2025
pulisher
Apr 17, 2025

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO - marketscreener.com

Apr 17, 2025

Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.39
price up icon 0.24%
$37.58
price up icon 1.54%
$109.55
price up icon 0.23%
$28.66
price up icon 2.10%
$111.66
price up icon 0.28%
biotechnology ONC
$288.18
price down icon 3.39%
Cap:     |  Volume (24h):